Shuster et al. reported the results of a phase 3 trial, in which the primary endpoint was disease-free survival (DFS), to define the clinical benefit of vaccination with hybridoma-derived autologous tumor Ig conjugated to KLH administered with GM-CSF [85]. The gene discussed is CSF2; the disease is neoplasm.